Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2
Head & Neck · 2024
DOI: 10.1002/hed.27787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2024. Verfasst von Ryosuke Sato und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan. Hauptthemen laut MEDLINE: Nivolumab, B7-H1 Antigen, Head and Neck Neoplasms, Programmed Cell Death 1 Ligand 2 Protein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Predictive biomarkers for nivolumab in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) have not yet been established.
Methods
The tumor proportion score (TPS), combined positive score (CPS), and soluble forms of programmed cell death ligand‐1 (PD‐L1) and programmed cell death ligand‐2 (PD‐L2) were retrospectively analyzed in patients with RMHNSCC treated with nivolumab.
Results
The positivity rates for TPS (PD‐L1), CPS (PD‐L1), TPS (PD‐L2), and CPS (PD‐L2) were 73.8%, 78.2%, 56.4%, and 78.2%, respectively. Patients with high TPS (PD‐L1), CPS (PD‐L1), or CPS (PD‐L1 and PD‐L2) showed significantly prolonged progression‐free survival. Favorable overall survival was associated with high CPS (PD‐L1 and PD‐L2) and low soluble PD‐L1 and PD‐L2 levels. The expressions of tissue and soluble PD‐L1/2 were not correlated.
Conclusions
Our study revealed that compared to PD‐L1 expression alone, dual expression of PD‐L1 and PD‐L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
- Department of Innovative Head & Neck Cancer Research and Treatment, Asahikawa Medical University, Asahikawa, Japan.
ORCID-Profile: Michihisa Kono, Takumi Kumai
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sato, R., Komatsuda, H., Inoue, T., Wakisaka, R., Kono, M., Yamaki, H., Ohara, K., Kumai, T., Kishibe, K., Hayashi, T., & Takahara, M. (2024). Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2. Head & Neck. https://doi.org/10.1002/hed.27787
Vancouver
Sato R, Komatsuda H, Inoue T, Wakisaka R, Kono M, Yamaki H, et al. Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2. Head & Neck. 2024. doi:10.1002/hed.27787
BibTeX
@article{Sato2024,
author = {Sato, Ryosuke and Komatsuda, Hiroki and Inoue, Takahiro and Wakisaka, Risa and Kono, Michihisa and Yamaki, Hidekiyo and Ohara, Kenzo and Kumai, Takumi and Kishibe, Kan and Hayashi, Tatsuya and Takahara, Miki},
title = {Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2},
journal = {Head & Neck},
year = {2024},
doi = {10.1002/hed.27787}
}
EUVIMED